



Published in final edited form as:

Genet Epidemiol. 2019 June ; 43(4): 449–457. doi:10.1002/gepi.22187.

A large-scale exome array analysis of venous thromboembolism

Sara Lindström^{1,2}, Jennifer A. Brody³, Constance Turman⁴, Marine Germain⁵, Traci M. Bartz^{3,6}, Erin N. Smith^{7,8}, Ming-Huei Chen⁹, Marja Puurunen¹⁰, Daniel Chasman¹¹, Jeffrey Hassler², Nathan Pankratz¹², Saonli Basu¹³, Weihua Guan¹³, Beata Gyorgy^{14,15}, Manal Ibrahim^{16,17,18}, Jean-Philippe Empana^{19,20}, Robert Olaso²¹, Rebecca Jackson²², Sigrid K. Brækkan^{8,23}, Barbara McKnight⁶, Jean-Francois Deleuze²¹, Cristopher J. O'Donnell²⁴, Xavier Jouven^{19,25}, Kelly A. Frazer^{7,8,26}, Bruce M. Psaty^{1,3,27,28}, Kerri L. Wiggins³, Kent Taylor²⁹, Alexander P. Reiner¹, Susan R. Heckbert¹, Charles Kooperberg², Paul Ridker¹¹, John-Bjarne Hansen^{8,23}, Weihong Tang³⁰, Andrew D. Johnson⁹, Pierre-Emmanuel Morange^{16,17,18}, David A. Trégouët⁵, Peter Kraft^{4,31}, Nicholas L. Smith^{1,28,32}, and Christopher Kabrhel^{33,34,35} INVENT Consortium.

¹Department of Epidemiology, University of Washington, Seattle, United States.

²Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States.

³Department of Medicine, University of Washington, Seattle, United States.

⁴Department of Epidemiology Harvard TH Chan School of Public Health, Boston, United States.

⁵University of Bordeaux, Inserm 1219, Bordeaux Population Health Research Center, Bordeaux, France.

⁶Department of Biostatistics University of Washington, Seattle, United States.

⁷Department of Pediatrics and Rady Children's Hospital University of California, San Diego, La Jolla, United State.

⁸Department of Clinical Medicine, UiT - The Arctic University of Norway, K.G. Jebsen Thrombosis Research and Expertise Center (TREC), Tromsø, Norway.

⁹Population Sciences Branch, National Heart, Lung and Blood Institute's The Framingham Heart Study, Framingham, United States.

¹⁰School of Medicine, Boston University, Boston, United States.

¹¹Division of Preventive Medicine, Brigham and Women's Hospital, Boston, United States.

¹²Department of Laboratory Medicine and Pathology, School of Medicine, University of Minnesota, Minneapolis, USA,

¹³Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, USA.

Corresponding author: Christopher Kabrhel, 55 Fruit Street, Boston, MA 02114-2696, ckabrhel@partners.org, Phone: 617-726-7622.

CONFLICT OF INTEREST:

No authors report a conflict of interest related to this work.

¹⁴Team Genomics & Pathophysiology of Cardiovascular Diseases, Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR_S 1166, Paris, France.

¹⁵ICAN Institute for Cardiometabolism and Nutrition, Paris, France.

¹⁶Laboratory of Haematology, La Timone Hospital, Marseille, France.

¹⁷Aix-Marseille University, INSERM, INRA, C2VN, Marseille, France.

¹⁸CRB Assistance Publique Hopitaux de Marseille HemoVasc, Marseille, France,

¹⁹Department of Epidemiology, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR_S 970, Paris, France.

²⁰Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

²¹Centre National de Recherche en Génomique Humaine (CNRGH), Direction de la Recherche Fondamentale, CEA, Institut de Biologie François Jacob, Evry, France.

²²Ohio State University, Columbus, United States.

²³Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.

²⁴Cardiology, Boston Veteran's Administration Healthcare, Boston, United States.

²⁵Department of Cardiology, Georges Pompidou European Hospital, APHP, Paris, France.

²⁶Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States.

²⁷Department of Health Services, University of Washington, Seattle, United States.

²⁸Kaiser Permanente Washington Research Institute, Kaiser Permanente Washington, Seattle, United States.

²⁹LA BioMed, Torrance, United States

³⁰Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, United States.

³¹Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, United States,

³²Department of Veteran Affairs Office of Research and Development, Seattle Epidemiologic Research and Information Center, Seattle, United States.

³³Center for Vascular Emergencies, Department of Emergency Medicine, Massachusetts General Hospital, Boston, United States,

³⁴Channing Network Medicine, Brigham and Women's Hospital, Boston, United States.

³⁵Harvard Medical School, Boston, United States

Abstract

Although recent genome-wide association studies have identified novel associations for common variants, there has been no comprehensive exome-wide search for low-frequency variants that affect the risk of venous thromboembolism (VTE). We conducted a meta-analysis of 11 studies comprising 8,332 cases and 16,087 controls of European ancestry and 382 cases and 1,476 controls of African-American ancestry genotyped with the Illumina HumanExome BeadChip. We

used the seqMeta package in R to conduct single variant and gene-based rare variant tests. In the single variant analysis, we limited our analysis to the 64,794 variants with at least 40 minor alleles across studies (minor allele frequency ~ 0.08%). We confirmed associations with previously identified VTE loci, including *ABO*, *F5*, *F11*, and *FGA*. After adjusting for multiple testing, we observed no novel significant findings in single variant or gene-based analysis. Given our sample size, we had >80% power to detect minimum odds ratios >1.5 and 1.8 for a single variant with minor allele frequency of 0.01 and 0.005, respectively. Larger studies and sequence data may be needed to identify novel low-frequency and rare variants associated with VTE risk.

INTRODUCTION

Candidate gene studies and genome-wide association studies (GWAS) have identified multiple genetic variants that are associated with venous thromboembolism (VTE), a condition spanning both pulmonary embolism (PE) and deep vein thrombosis (DVT). The majority of genetic variants associated with VTE have been located in genes known to be involved in hemostasis, such as *ABO*, *F2*, *F5*, *F11*, *FGG* and *PROCR* (Crous-Bou et al., 2016). Associations have also been observed for variants located in genes outside known hemostasis pathways, such as *TSPAN15* and *SLC44A2* (Germain et al., 2015), and the exact mechanisms by which these genes influence VTE risk have yet to be determined.

Despite these successes, much of the heritability of VTE remains unexplained. A recent study based on 3,290 VTE cases and 116,868 controls from the UK Biobank estimated the heritability due to genotyped and imputed SNPs to be ~30% (Klarin et al., 2017), and twin studies have estimated VTE heritability to be as high as ~ 50% (Heit et al., 2004). However, the UK Biobank study also noted that known variants only explain 5% of VTE heritability. Thus, additional genetic variants that contribute to VTE risk remain to be discovered.

Recently developed exome arrays (Huyghe et al., 2013) allow for cost-efficient genotyping of 240,000 coding variants identified through the NHLBI Exome Sequencing Project (Tennessen et al., 2012). Based on exome and whole-genome sequencing data from 9,000 subjects of European ancestry, 2,000 subjects of African ancestry and 500 subjects each of Hispanic and Asian ancestry, 240,000 SNPs were selected for inclusion on the exome array. To be selected, non-synonymous variants had to be seen at least three times in at least two datasets whereas splice and stop variants had to be seen at least two times and in at least two datasets. The exome array has proven to be an efficient tool for identifying low-frequency coding variants associated with blood and cardiovascular traits including: hypertension (Surendran et al., 2016, Liu et al., 2016), hematological traits (Eicher et al., 2016, Chen et al., 2017), (Chami et al., 2016, Mousas et al., 2017), lipid levels (Peloso et al., 2014), coronary artery disease (Myocardial Infarction et al., 2016), and atrial fibrillation (Christophersen et al., 2017). However, no study has published a comprehensive investigation of the association between low-frequency exonic variants and VTE.

We hypothesized that exonic, low-frequency genetic variation would be associated with VTE. We meta-analyzed exome array genotype data from 11 European and US studies, totaling 8,723 VTE cases and 17,563 controls. We conducted both single-variant and gene-based tests to identify novel genetic variants associated with VTE risk.

MATERIALS AND METHODS

Study participants

All study participants were either of European or African-American ancestry and came from eight US-based cohorts (ARIC, CHS, FHS, HPFS, NHS, NHSII, WGHS and WHI), one US-based case-control study (HVH), one Norwegian case-control study (Tromsø) and one French case-control study (MARTHA)(ARIC Investigators, 1989, Fried et al., 1991, Tell et al., 1993, Germain et al., 2011, Hankinson et al., 1995, Tworoger et al., 2006, Ridker et al., 2008, Solomon et al., 2016, Kannel et al., 1961, Giovannucci et al., 1995, Heckbert et al., 2008, Women's Health Initiative Study Group, 1998, Psaty et al., 2009) (Table 1). Details of each study have been previously published(ARIC Investigators, 1989, Fried et al., 1991, Tell et al., 1993, Germain et al., 2011, Hankinson et al., 1995, Tworoger et al., 2006, Ridker et al., 2008, Solomon et al., 2016, Kannel et al., 1961, Giovannucci et al., 1995, Heckbert et al., 2008, Women's Health Initiative Study Group, 1998). Physician-diagnosed VTE was identified either through hospital records or validated self-reports, supplemented by review of medical records. A detailed description of the study-specific design and characteristics is presented in Supplementary Table 1. All participating studies were approved by their respective institutional review board and informed consent for genetic analyses was obtained from each study participant.

Genotyping and quality control

Genotyping was conducted using either the Illumina HumanExome BeadChip v1.0, Illumina HumanExome BeadChip v1.1 or the Illumina HumanCore Exome BeadChip v1.1, depending on study. Genotypes from 765 samples from the Tromsø study were obtained from exome sequencing rather than genotyping. Genotypes were called using either GenomeStudio or Zcall. Each study conducted data cleaning and quality assurance checks following a common protocol. Details of study-specific genotype calling and quality control can be found in Supplementary Table 1.

We conducted gene set enrichment analysis using the GSEAPreranked algorithm as implemented in the GenePattern software and the KEGG, Gene Ontology, and Hallmarks pathway sets(Mootha et al., 2003, Subramanian et al., 2005). We applied GSEAPreranked to four sets of results (1) Burden test of variants using a broad definition, (2) Burden test of variants using a strict definition, (3) SKAT test of variants using a broad definition, (4) SKAT test of variants using a strict definition.

One of the included studies (MARTHA) genotyped cases and controls on separate platforms (cases were genotyped on Illumina HumanExome 12v.1-2_A and controls were genotyped with the Illumina HumanExome 12v.1_A array). We identified a moderate inflation in test statistics ($\lambda_{1000}=1.09$) in MARTHA for the single variant analysis with $MAF>0.005$. Therefore, we re-meta-analyzed the data while excluding MARTHA, leaving a total of 6,095 cases and 14,149 controls in a sensitivity analysis.

Statistical Methods

Each study conducted individual analysis following a common protocol. To avoid type-1 error inflation (Ma et al., 2013), studies with more than four controls per case randomly selected a maximum of four controls for each case (i.e. 1:4 case:control ratio). Those studies that performed control selection (ARIC, CHS, FHS, WGHS and WHI) reviewed the distribution of age and sex following control selection to ensure roughly equal distributions among cases and controls. Each study conducted both single variant and gene-based analysis. Association analysis were based on logistic regression adjusting for age, sex, principal components and other study-specific variables (as needed). Analyses were conducted using the seqMeta (Voorman A, 2017) package in R which produces study-specific results. Each study sent their study-specific results to the coordinating center at Harvard T.H. Chan School of Public Health where the meta-analyses took place.

For single variant analysis, we conducted a meta-analysis of the study-specific score statistics based on an additive coding. We limited our analysis to the 64,794 variants that had at least 40 minor alleles across studies (corresponding to a minor allele frequency of ~ 0.08%). Bonferroni correction for the number of variants tested was used to set the significance threshold for the analysis corresponding to $P < 7.7 \times 10^{-7}$ (0.05/64,794 variants).

For the gene-based rare variant analyses, we conducted two tests: Weighted-Sum Burden (Madsen and Browning, 2009) (WSB) test as implemented in seqMeta (Voorman A, 2017) and SKAT (Wu et al., 2011). We applied two different sets of criteria to select variants, based on coding variant annotation from five prediction algorithms (PolyPhen2, HumDiv and HumVar, LRT, MutationTaster and SIFT) (Purcell et al., 2014). The 'broad' definition included variants with a minor allele frequency (MAF) < 0.01 that were nonsense, stop-loss, splice site, as well as missense variants that are annotated as damaging by at least one prediction algorithm. The 'strict' definition included only variants with a MAF < 0.01 that were nonsense, stop-loss, splice-site, as well as missense variants annotated as damaging by all five algorithms. For the SKAT analysis, variants were weighted according to the beta density function as previously described (Wu et al., 2011). We excluded all genes that had fewer than two variants included in the analysis. In total, we tested 15,041 genes using the broad definition and 5,749 genes using the strict definition. Bonferroni correction for the number of genes and tests performed was used to set the significance threshold for the gene-based analysis corresponding to $P < 1.2 \times 10^{-6}$ (0.05/41,580 tests [(5,749+15,041) genes \times 2 tests]).

One of the included studies (MARTHA) genotyped cases and controls on separate platforms (cases were genotyped on Illumina HumanExome 12v.1-2_A and controls were genotyped with the Illumina HumanExome 12v.1_A array. We identified a moderate inflation in test statistics ($\lambda_{1000} = 1.09$) in MARTHA for the single variant analysis with MAF > 0.005. Therefore, we reran the analysis excluding MARTHA, leaving a total of 6,095 cases and 14,149 controls in a sensitivity analysis.

RESULTS

Single Variant Analysis

After excluding all variants with $MAC < 40$ (corresponding to a minor allele frequency of $\sim 0.08\%$) in the combined study population, single variant meta-analysis showed no sign of genomic inflation ($\lambda_{1000} = 1.03$, Supplementary Figure 1). The strongest association was observed for rs635634 at the *ABO* locus (OR=1.60, 95% CI: 1.52–1.68, $P = 1.51 \times 10^{-73}$). In addition, we observed significant associations for previously known genes including the *F5*, *FGG*, and *F11* (Supplementary Table 2). The most strongly associated rare (MAF < 0.01) variant we observed was rs121918472 (OR=1.93, 95% CI: 1.46–2.56, $P = 3.55 \times 10^{-6}$), a non-synonymous variant located in the Protein S (*PROS1*) gene, also known as the p.Ser501Pro or PS Herleen mutation, MAF=0.005. This variant is also known to be associated with VTE (Suchon et al., 2017). After excluding known loci, only one single variant remained significant after adjusting for multiple testing but this signal was driven exclusively by the MARTHA study ($p = 1.96 \times 10^{-15}$ when including MARTHA, $p = 0.37$ after excluding MARTHA). As the signal at this locus is most likely due to technical issues, we removed it from further analysis. No other variant reached genome-wide significance ($P < 7.7 \times 10^{-7}$). The strongest sub-threshold association was observed for rs755109, a common (MAF=0.37) variant previously associated with thyroid stimulating hormones (OR=1.10, 95% CI: 1.06–1.16, $P = 3.31 \times 10^{-6}$).

Weighted-Sum Burden (WSB) Rare Variant Analysis

No gene reached the pre-determined significance threshold of $P < 1.2 \times 10^{-6}$ (Figure 1). The top three associated genes using the ‘broad’ and ‘strict’ definitions are shown in Table 2 and all associations with $p < 0.01$ are shown in Supplementary Tables 3 & 4. The *SERPINA10* gene on chromosome 14 was the third strongest associated gene using the broad ($p = 0.0002$) and the strict ($p = 0.0007$) definition. *SERPINA10* is expressed primarily in the liver and mutations in this gene have previously been linked to VTE (Van de Water et al., 2004, Corral et al., 2006).

SKAT Rare Variant Analysis

No gene reached the pre-determined significance threshold of $P < 1.2 \times 10^{-6}$ (Figure 1). The top three associated genes using the ‘broad’ and ‘strict’ definitions are shown in Table 2 and all associations with $p < 0.01$ are shown in Supplementary Tables 5 & 6.

Gene Set Enrichment Analysis

Gene set enrichment analysis based on the results obtained from WSB and SKAT did not yield any significant pathway after adjusting for number of pathways tested (all FDR $q > 0.08$, data not shown).

DISCUSSION

To assess the contribution of rare coding variation to VTE risk, we combined data from 11 studies spanning four countries, resulting in exome array data on 8,723 VTE cases and 17,563 controls. By comparison, the number of cases included in this study is larger than the

largest GWAS of VTE published to date (Germain et al., 2015). Beyond known associations, we did not observe evidence that additional low-frequency and rare coding variants with moderate-to-large effects contribute to VTE risk.

Although our study is the largest genomic study of VTE to date, our ability to identify rare variants associated with VTE was limited by low statistical power. Given our sample size, we had >80% power to detect minimum odds ratios of 1.56 and 1.81 for a single variant with MAF = 0.01 and 0.005, respectively. It is estimated that the exome array includes 97–98% of non-synonymous variants and 94–95% of stop variants that would have been detected in an average genome through exome sequencing (https://genome.sph.umich.edu/wiki/Exome_Chip_Design). Thus, it is possible that we missed coding variants associated with VTE, especially if such variants are particularly rare in individuals who are not affected with VTE. Another limitation with this study is the limited contribution of non-European populations to our analyses, with 93% of our study population being of European ancestry.

Identifying risk factors for VTE, including genetic risk factors, is of great public health importance. VTE affects 1–2/1000 Americans yearly. The incidence has been increasing and mortality from PE remains high (Arshad et al., 2017, Heit et al., 2017, Silverstein et al., 1998, Heit, 2005). The mortality of VTE is greatest in the first 24 hours, and for one-fourth of PE patients, the initial clinical presentation is sudden death (Goldhaber et al., 1999, Courtney and Kline, 2001, Cohen et al., 2007). Therefore, our ability to improve mortality hinges on primary prevention, identifying patients at risk for VTE, and understanding the underlying pathophysiology of the disease. Despite the accumulated evidence that genetic factors play a major role in the pathophysiology of VTE, only 35% of VTE patients undergoing testing for thrombophilia carry a polymorphism known to increase VTE risk (Cushman, 2005). Additional efforts to identify genetic variants associated with VTE risk are still needed.

The INVENT Consortium is a well-established collaboration of genetic studies of VTE and, to our knowledge, our meta-analysis includes data from the vast majority of exome array studies of VTE. Additional large studies, potentially including comprehensive sequencing data, may be needed to identify novel low-frequency rare coding variants associated with VTE. Further research into the genetic basis of VTE is needed to aid in the primary prevention of this potentially fatal disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

ARIC: The Atherosclerosis Risk in Communities (ARIC) study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I). The authors thank the staff and participants of the ARIC study for their important contributions. Funding for LITE was supported by R01HL59367. Funding support for “Building on GWAS for NHLBI-diseases: the U.S. CHARGE consortium” was provided by the NIH through the American Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419).

CHS: Cardiovascular Health Study: This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, R01HL130114, and R01HL068986 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at [CHS-NHLBI.org](https://www.chs-nhlbi.org). The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

FHS: The Framingham Heart Study is conducted and supported by the NHLBI in collaboration with Boston University (Contract No. N01-HC-25195). Genotyping, quality control, and calling of the Illumina HumanExome BeadChip in the Framingham Heart Study were supported by funding from the National Heart, Lung and Blood Institute Division of Intramural Research (Daniel Levy and Christopher J. O'Donnell, Principal Investigators). Support for the centralized genotype calling was provided by Building on GWAS for NHLBI-diseases: the U.S. CHARGE consortium through the National Institutes of Health (NIH) American Recovery and Reinvestment Act of 2009 (5RC2HL102419). M.H.C. and A.D.J. were supported by National Heart, Lung and Blood Institute Division of Intramural Research funds. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

HVH: The research of the Heart and Vascular Health Studies has been funded in part by National Institute of Health grants HL040628, HL043201, HL053375, HL060739, HL68639, HL068986, HL073410, HL74745, HL085251, HL095080.

MARTHA genetics project was supported by the GENMED Laboratory of Excellence on Medical Genomics (ANR-10-LABX-0013), the French Clinical Research Infrastructure Network on Venous Thrombo-Embolic (F-CRIN INNOVTE) and the ICAN Institute for Cardiometabolism and Nutrition (ANR-10-IAHU), three research programs managed by the National Research Agency (ANR) part of the French Investment for the Future initiative.

NHS/NHSII/HPFS - These studies received grant supports P01CA87969, R01CA49449, R01HL034594, R01HL088521, R01CA50385, R01CA67262, P01CA055075, R01HL35464, R01HL116854. We thank all of the researchers and staff whose hard work made each of the contributing studies possible.

Tromsø: This work was supported by an independent grant from Stiftelsen Kristian Gerhard Jebsen in Norway.

WGHS: The Women's Genome Health Study is funded by the National Heart, Lung, and Blood Institute (HL043851, HL080467, HL099355) and the National Cancer Institute (CA047988 and UM1CA182913), with support for genotyping provided by Amgen.

WHI: The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.

GRANT NUMBERS (also see ACKNOWLEDGEMENTS):

ARIC and LITE: HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, HHSN268201700005I, R01HL59367, 5RC2HL102419.

CHS: HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, R01HL130114, R01HL068986, R01AG023629, UL1TR000124, DK063491

FHS: N01-HC-25195, 5RC2HL102419

HVH: HL040628, HL043201, HL053375, HL060739, HL68639, HL068986, HL073410, HL74745, HL085251, HL095080.

MARTHA: ANR-10-LABX-0013, ANR-10-IAHU.

NHS/NHSII/HPFS - P01CA87969, R01CA49449, R01HL034594, R01HL088521, R01CA50385, R01CA67262, P01CA055075, R01HL35464, R01HL116854.

WGHS: HL043851, HL080467, HL099355, CA047988, UM1CA182913.

WHI: HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.

REFERENCES

- ARIC INVESTIGATORS 1989 The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. *Am J Epidemiol*, 129, 687–702. [PubMed: 2646917]
- ARSHAD N, ISAKSEN T, HANSEN JB & BRAEKKAN SK 2017 Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population. *Eur J Epidemiol*, 32, 299–305. [PubMed: 28314981]
- CHAMI N, CHEN MH, SLATER AJ, EICHER JD, EVANGELOU E, TAJUDDIN SM, LOVE-GREGORY L, KACPROWSKI T, SCHICK UM, NOMURA A, GIRI A, LESSARD S, BRODY JA, SCHURMANN C, PANKRATZ N, YANEK LR, MANICHAIKUL A, PAZOKI R, MIHAILOV E, HILL WD, RAFFIELD LM, BURT A, BARTZ TM, BECKER DM, BECKER LC, BOERWINKLE E, BORK-JENSEN J, BOTTINGER EP, O'DONOGHUE ML, CROSSLIN DR, DE DENUS S, DUBE MP, ELLIOTT P, ENGSTROM G, EVANS MK, FLOYD JS, FORNAGE M, GAO H, GREINACHER A, GUDNASON V, HANSEN T, HARRIS TB, HAYWARD C, HERNESNIEMI J, HIGHLAND HM, HIRSCHHORN JN, HOFMAN A, IRVIN MR, KAHONEN M, LANGE E, LAUNER LJ, LEHTIMAKI T, LI J, LIEWALD DC, LINNEBERG A, LIU Y, LU Y, LYYTIKAINEN LP, MAGI R, MATHIAS RA, MELANDER O, METSPALU A, MONONEN N, NALLS MA, NICKERSON DA, NIKUS K, O'DONNELL CJ, ORHO-MELANDER M, PEDERSEN O, PETERSMANN A, POLFUS L, PSATY BM, RAITAKARI OT, RAITOHARJU E, RICHARD M, RICE KM, RIVADENEIRA F, ROTTER JI, SCHMIDT F, SMITH AV, STARR JM, TAYLOR KD, TEUMER A, THUESEN BH, TORSTENSON ES, TRACY RP, TZOULAKI I, ZAKAI NA, VACCHI-SUZZI C, VAN DUJNCM, VAN ROOIJFJ, CUSHMAN M, DEARY IJ, VELEZ EDWARDS DR, VERGNAUD AC, WALLENTIN L, WATERWORTH DM, WHITE HD, WILSON JG, ZONDERMAN AB, et al. 2016 Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. *Am J Hum Genet*, 99, 8–21. [PubMed: 27346685]
- CHEN MH, YANEK LR, BACKMAN JD, EICHER JD, HUFFMAN JE, BEN-SHLOMO Y, BESWICK AD, YERGES-ARMSTRONG LM, SHULDINER AR, O'CONNELL JR, MATHIAS RA, BECKER DM, BECKER LC, LEWIS JP, JOHNSON AD & FARADAY N 2017 Exome-chip meta-analysis identifies association between variation in ANKRD26 and platelet aggregation. *Platelets*, 1–10.
- CHRISTOPHERSEN IE, RIENSTRA M, ROSELLI C, YIN X, GEELHOED B, BARNARD J, LIN H, ARKING DE, SMITH AV, ALBERT CM, CHAFFIN M, TUCKER NR, LI M, KLARIN D, BIHLMEYER NA, LOW SK, WEEKE PE, MULLER-NURASYID M, SMITH JG, BRODY JA, NIEMEIJER MN, DORR M, TROMPET S, HUFFMAN J, GUSTAFSSON S, SCHURMANN C, KLEBER ME, LYYTIKAINEN LP, SEPPALA I, MALIK R, HORIMOTO A, PEREZ M, SINISALO J, AESCHBACHER S, THERIAULT S, YAO J, RADMANESH F, WEISS S, TEUMER A, CHOI SH, WENG LC, CLAUSS S, DEO R, RADER DJ, SHAH SH, SUN A, HOPEWELL JC, DEBETTE S, CHAUHAN G, YANG Q, WORRALL BB, PARE G, KAMATANI Y, HAGEMEIJER YP, VERWEIJ N, SILAND JE, KUBO M, SMITH JD, VAN WAGONER DR, BIS JC, PERZ S, PSATY BM, RIDKER PM, MAGNANI JW, HARRIS TB, LAUNER LJ, SHOEMAKER MB, PADMANABHAN S, HAESSLER J, BARTZ TM, WALDENBERGER M, LICHTNER P, ARENDT M, KRIEGER JE, KAHONEN M, RISCH L, MANSUR AJ, PETERS A, SMITH BH, LIND L, SCOTT SA, LU Y, BOTTINGER EB, HERNESNIEMI J, LINDGREN CM, WONG JA, HUANG J, ESKOLA M, MORRIS AP, FORD I, REINER AP, DELGADO G, CHEN LY, CHEN YI, SANDHU RK, LI M, BOERWINKLE E, EISELE L, LANNFELT L, ROST N, et al. 2017 Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. *Nat Genet*, 49, 946–952. [PubMed: 28416818]
- COHEN AT, AGNELLI G, ANDERSON FA, ARCELUS JI, BERGQVIST D, BRECHT JG, GREER IA, HEIT JA, HUTCHINSON JL, KAKKAR AK, MOTTIER D, OGER E, SAMAMA MM, SPANNAGL M & EUROPE VTEIAGI 2007 Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost*, 98, 756–64. [PubMed: 17938798]

- CORRAL J, GONZALEZ-CONEJERO R, SORIA JM, GONZALEZ-PORRAS JR, PEREZ-CEBALLOS E, LECUMBERRI R, ROLDAN V, SOUTO JC, MINANO A, HERNANDEZ-ESPINOSA D, ALBERCA I, FONTCUBERTA J & VICENTE V 2006 A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. *Blood*, 108, 177–83. [PubMed: 16527896]
- COURTNEY DM & KLINE JA 2001 Identification of prearrest clinical factors associated with outpatient fatal pulmonary embolism. *Acad Emerg Med*, 8, 1136–42. [PubMed: 11733290]
- CROUS-BOU M, HARRINGTON LB & KABRHEL C 2016 Environmental and Genetic Risk Factors Associated with Venous Thromboembolism. *Semin Thromb Hemost*, 42, 808–820. [PubMed: 27764878]
- CUSHMAN M 2005 Inherited risk factors for venous thrombosis. *Hematology Am Soc Hematol Educ Program*, 452–7. [PubMed: 16304419]
- EICHER JD, CHAMI N, KACPROWSKI T, NOMURA A, CHEN MH, YANEK LR, TAJUDDIN SM, SCHICK UM, SLATER AJ, PANKRATZ N, POLFUS L, SCHURMANN C, GIRI A, BRODY JA, LANGE LA, MANICHAIKUL A, HILL WD, PAZOKI R, ELLIOT P, EVANGELOU E, TZOULAKI I, GAO H, VERGNAUD AC, MATHIAS RA, BECKER DM, BECKER LC, BURT A, CROSSLIN DR, LYYTIKAINEN LP, NIKUS K, HERNESNIEMI J, KAHONEN M, RAITOHARJU E, MONONEN N, RAITAKARI OT, LEHTIMAKI T, CUSHMAN M, ZAKAI NA, NICKERSON DA, RAFFIELD LM, QUARELLS R, WILLER CJ, PELOSO GM, ABECASIS GR, LIU DJ, GLOBAL LIPIDSGENETICSC, DELOUKAS P, SAMANI NJ, SCHUNKERT H, ERDMANN J, CONSORTIUM CAE, MYOCARDIAL INFARCTIONGENETICSC, FORNAGE M, RICHARD M, TARDIF JC, RIOUX JD, DUBE MP, DE DENUS S, LU Y, BOTTINGER EP, LOOS RJ, SMITH AV, HARRIS TB, LAUNER LJ, GUDNASON V, VELEZ EDWARDS DR, TORSTENSON ES, LIU Y, TRACY RP, ROTTER JI, RICH SS, HIGHLAND HM, BOERWINKLE E, LI J, LANGE E, WILSON JG, MIHAILOV E, MAGI R, HIRSCHHORN J, METSPALU A, ESKO T, VACCHI-SUZZI C, NALLS MA, ZONDERMAN AB, EVANS MK, ENGSTROM G, ORHO-MELANDER M, MELANDER O, O'DONOGHUE ML, WATERWORTH DM, WALLENTIN L, WHITE HD, FLOYD JS, BARTZ TM, RICE KM, PSATY BM, STARR JM, LIEWALD DC, HAYWARD C, DEARY IJ, et al. 2016 Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. *Am J Hum Genet*, 99, 40–55. [PubMed: 27346686]
- FRIED LP, BORHANI NO, ENRIGHT P, FURBERG CD, GARDIN JM, KRONMAL RA, KULLER LH, MANOLIO TA, MITTELMARK MB, NEWMAN A & et al. 1991 The Cardiovascular Health Study: design and rationale. *Ann Epidemiol*, 1, 263–76. [PubMed: 1669507]
- GERMAIN M, CHASMAN DI, DE HAAN H, TANG W, LINDSTROM S, WENG LC, DE ANDRADE M, DE VISSER MC, WIGGINS KL, SUCHON P, SAUT N, SMADJA DM, LE GAL G, VAN HYLCKAMA VLIEG A, DI NARZO A, HAO K, NELSON CP, ROCANIN-ARJO A, FOLKERSEN L, MONAJEMI R, ROSE LM, BRODY JA, SLAGBOOM E, AISSI D, GAGNON F, DELEUZE JF, DELOUKAS P, TZOURIO C, DARTIGUES JF, BERR C, TAYLOR KD, CIVELEK M, ERIKSSON P, CARDIOGENICS C, PSATY BM, HOUWING-DUITERMAAT J, GOODALL AH, CAMBIEN F, KRAFT P, AMOUYEL P, SAMANI NJ, BASU S, RIDKER PM, ROSENDAAL FR, KABRHEL C, FOLSOM AR, HEIT J, REITSMA PH, TREGOUET DA, SMITH NL & MORANGE PE 2015 Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. *Am J Hum Genet*, 96, 532–42. [PubMed: 25772935]
- GERMAIN M, SAUT N, GRELICHE N, DINA C, LAMBERT JC, PERRET C, COHEN W, OUDOT-MELLAKH T, ANTONI G, ALESSI MC, ZELENKA D, CAMBIEN F, TIRET L, BERTRAND M, DUPUY AM, LETENNEUR L, LATHROP M, EMMERICH J, AMOUYEL P, TREGOUET DA & MORANGE PE 2011 Genetics of venous thrombosis: insights from a new genome wide association study. *PLoS One*, 6, e25581. [PubMed: 21980494]
- GIOVANNUCCI E, ASCHERIO A, RIMM EB, STAMPFER MJ, COLDITZ GA & WILLETT WC 1995 Intake of carotenoids and retinol in relation to risk of prostate cancer. *J Natl Cancer Inst*, 87, 1767–76. [PubMed: 7473833]
- GOLDHABER SZ, VISANI L & DE ROSA M 1999 Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). *Lancet*, 353, 1386–9. [PubMed: 10227218]

- HANKINSON SE, COLDITZ GA, HUNTER DJ, MANSON JE, WILLETT WC, STAMPFER MJ, LONGCOPE C & SPEIZER FE 1995 Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States). *Cancer Causes Control*, 6, 217–24. [PubMed: 7612801]
- HECKBERT SR, LI G, CUMMINGS SR, SMITH NL & PSATY BM 2008 Use of alendronate and risk of incident atrial fibrillation in women. *Arch Intern Med*, 168, 826–31. [PubMed: 18443257]
- HEIT JA 2005 Venous thromboembolism: disease burden, outcomes and risk factors. *J Thromb Haemost*, 3, 1611–7. [PubMed: 16102026]
- HEIT JA, ASHRANI A, CRUSAN DJ, MCBANE RD, PETTERSON TM & BAILEY KR 2017 Reasons for the persistent incidence of venous thromboembolism. *Thromb Haemost*, 117, 390–400. [PubMed: 27975103]
- HEIT JA, PHELPS MA, WARD SA, SLUSSER JP, PETTERSON TM & DE ANDRADE M 2004 Familial segregation of venous thromboembolism. *J Thromb Haemost*, 2, 731–6. [PubMed: 15099278]
- HUYGHE JR, JACKSON AU, FOGARTY MP, BUCHKOVICH ML, STANCAKOVA A, STRINGHAM HM, SIM X, YANG L, FUCHSBERGER C, CEDERBERG H, CHINES PS, TESLOVICH TM, ROMM JM, LING H, MCMULLEN I, INGERSOLL R, PUGH EW, DOHENY KF, NEALE BM, DALY MJ, KUUSISTO J, SCOTT LJ, KANG HM, COLLINS FS, ABECASIS GR, WATANABE RM, BOEHNKE M, LAAKSO M & MOHLKE KL 2013 Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion. *Nat Genet*, 45, 197–201. [PubMed: 23263489]
- KANNEL WB, DAWBER TR, KAGAN A, REVOTSKIE N & STOKES J 3RD 1961 Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. *Ann Intern Med*, 55, 33–50. [PubMed: 13751193]
- KLARIN D, EMDIN CA, NATARAJAN P, CONRAD MF, CONSORTIUM I & KATHIRESAN S 2017 Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor. *Circ Cardiovasc Genet*, 10.
- LIU C, KRAJA AT, SMITH JA, BRODY JA, FRANCESCHINI N, BIS JC, RICE K, MORRISON AC, LU Y, WEISS S, GUO X, PALMAS W, MARTIN LW, CHEN YD, SURENDRAN P, DRENOS F, COOK JP, AUER PL, CHU AY, GIRI A, ZHAO W, JAKOBSDOTTIR J, LIN LA, STAFFORD JM, AMIN N, MEI H, YAO J, VOORMAN A, CONSORTIUM CHDE, EXOME BPC, GO TDC, CONSORTIUM TDG, LARSON MG, GROVE ML, SMITH AV, HWANG SJ, CHEN H, HUAN T, KOSOVA G, STITZIEL NO, KATHIRESAN S, SAMANI N, SCHUNKERT H, DELOUKAS P, MYOCARDIAL INFARCTIONG, CONSORTIA CAE, LI M, FUCHSBERGER C, PATTARO C, GORSKI M, CONSORTIUM CK, KOOPERBERG C, PAPANICOLAOU GJ, ROSSOUW JE, FAUL JD, KARDIA SL, BOUCHARD C, RAFFEL LJ, UITTERLINDEN AG, FRANCO OH, VASAN RS, O'DONNELL CJ, TAYLOR KD, LIU K, BOTTINGER EP, GOTTESMAN O, DAW EW, GIULIANINI F, GANESH S, SALFATI E, HARRIS TB, LAUNER LJ, DORR M, FELIX SB, RETTIG R, VOLZKE H, KIM E, LEE WJ, LEE IT, SHEU WH, TSOSIE KS, EDWARDS DR, LIU Y, CORREA A, WEIR DR, VOLKER U, RIDKER PM, BOERWINKLE E, GUDNASON V, REINER AP, VAN DUIJN CM, BORECKI IB, EDWARDS TL, CHAKRAVARTI A, ROTTER JI, PSATY BM, LOOS RJ, FORNAGE M, EHRET GB, NEWTON-CHEH C, et al. 2016 Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. *Nat Genet*, 48, 1162–70. [PubMed: 27618448]
- MA C, BLACKWELL T, BOEHNKE M, SCOTT LJ & GO TDI 2013 Recommended joint and meta-analysis strategies for case-control association testing of single low-count variants. *Genet Epidemiol*, 37, 539–50. [PubMed: 23788246]
- MADSEN BE & BROWNING SR 2009 A groupwise association test for rare mutations using a weighted sum statistic. *PLoS Genet*, 5, e1000384. [PubMed: 19214210]
- MOOHTHA VK, LINDGREN CM, ERIKSSON KF, SUBRAMANIAN A, SIHAG S, LEHAR J, PUIGSERVER P, CARLSSON E, RIDDERSTRALE M, LAURILA E, HOUSTIS N, DALY MJ, PATTERSON N, MESIROV JP, GOLUB TR, TAMAYO P, SPIEGELMAN B, LANDER ES, HIRSCHHORN JN, ALTSHULER D & GROOP LC 2003 PGC-1alpha-responsive genes involved

in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet*, 34, 267–73. [PubMed: 12808457]

- MOUSAS A, NTRITSOS G, CHEN MH, SONG C, HUFFMAN JE, TZOULAKI I, ELLIOTT P, PSATY BM, BLOOD-CELL C, AUER PL, JOHNSON AD, EVANGELOU E, LETTRE G & REINER AP 2017 Rare coding variants pinpoint genes that control human hematological traits. *PLoS Genet*, 13, e1006925. [PubMed: 28787443]
- MYOCARDIAL INFARCTION, INVESTIGATORS CAEC, STITZIEL NO, STIRRUPS KE, MASCA NG, ERDMANN J, FERRARIO PG, KONIG IR, WEEKE PE, WEBB TR, AUER PL, SCHICK UM, LU Y, ZHANG H, DUBE MP, GOEL A, FARRALL M, PELOSO GM, WON HH, DO R, VAN IPEREN E, KANONI S, KRUPPA J, MAHAJAN A, SCOTT RA, WILLENBERG C, BRAUND PS, VAN CAPELLEVEEN JC, DONEY AS, DONNELLY LA, ASSELTA R, MERLINI PA, DUGA S, MARZILIANO N, DENNY JC, SHAFFER CM, EL-MOKHTARI NE, FRANKE A, GOTTESMAN O, HEILMANN S, HENGSTENBERG C, HOFFMAN P, HOLMEN OL, HVEEM K, JANSSON JH, JOCKEL KH, KESSLER T, KRIEBEL J, LAUGWITZ KL, MAROULI E, MARTINELLI N, MCCARTHY MI, VAN ZUYDAM NR, MEISINGER C, ESKO T, MIHAILOV E, ESCHER SA, ALVER M, MOEBUS S, MORRIS AD, MULLER-NURASYID M, NIKPAY M, OLIVIERI O, LEMIEUX PERREAULT LP, ALQARAWI A, ROBERTSON NR, AKINSANYA KO, REILLY DF, VOGT TF, YIN W, ASSELBERGS FW, KOOPERBERG C, JACKSON RD, STAHL E, STRAUCH K, VARGA TV, WALDENBERGER M, ZENG L, KRAJA AT, LIU C, EHRET GB, NEWTON-CHEH C, CHASMAN DI, CHOWDHURY R, FERRARIO M, FORD I, JUKEMA JW, KEE F, KUULASMAA K, NORDESTGAARD BG, PEROLA M, SALEHEEN D, SATTAR N, SURENDRAN P, TREGOUET D, YOUNG R, HOWSON JM, BUTTERWORTH AS, DANESH J, ARDISSINO D, et al. 2016 Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. *N Engl J Med*, 374, 1134–44. [PubMed: 26934567]
- PELOSO GM, AUER PL, BIS JC, VOORMAN A, MORRISON AC, STITZIEL NO, BRODY JA, KHETARPAL SA, CROSBY JR, FORNAGE M, ISAACS A, JAKOBSDOTTIR J, FEITOSA MF, DAVIES G, HUFFMAN JE, MANICHAIKUL A, DAVIS B, LOHMAN K, JOON AY, SMITH AV, GROVE ML, ZANONI P, REDON V, DEMISSIE S, LAWSON K, PETERS U, CARLSON C, JACKSON RD, RYCKMAN KK, MACKAY RH, ROBINSON JG, SISCOVICK DS, SCHREINER PJ, MYCHALECKYJ JC, PANKOW JS, HOFMAN A, UITTERLINDEN AG, HARRIS TB, TAYLOR KD, STAFFORD JM, REYNOLDS LM, MARIONI RE, DEGHAN A, FRANCO OH, PATEL AP, LU Y, HINDY G, GOTTESMAN O, BOTTINGER EP, MELANDER O, ORHO-MELANDER M, LOOS RJ, DUGA S, MERLINI PA, FARRALL M, GOEL A, ASSELTA R, GIRELLI D, MARTINELLI N, SHAH SH, KRAUS WE, LI M, RADER DJ, REILLY MP, MCPHERSON R, WATKINS H, ARDISSINO D, PROJECT NGENES, ZHANG Q, WANG J, TSAI MY, TAYLOR HA, CORREA A, GRISWOLD ME, LANGE LA, STARR JM, RUDAN I, EIRIKSDOTTIR G, LAUNER LJ, ORDOVAS JM, LEVY D, CHEN YD, REINER AP, HAYWARD C, POLASEK O, DEARY IJ, BORECKI IB, LIU Y, GUDNASON V, WILSON JG, VAN DUJN CM, KOOPERBERG C, RICH SS, PSATY BM, ROTTER JI, O'DONNELL CJ, RICE K, BOERWINKLE E, KATHIRESAN S & CUPPLES LA 2014 Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. *Am J Hum Genet*, 94, 223–32. [PubMed: 24507774]
- PSATY BM, O'DONNELL CJ, GUDNASON V, LUNETTA KL, FOLSOM AR, ROTTER JI, UITTERLINDEN AG, HARRIS TB, WITTEMAN JC, BOERWINKLE E & CONSORTIUM C 2009 Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. *Circ Cardiovasc Genet*, 2, 73–80. [PubMed: 20031568]
- PURCELL SM, MORAN JL, FROMER M, RUDERFER D, SOLOVIEFF N, ROUSSOS P, O'DUSHLAINE C, CHAMBERT K, BERGEN SE, KAHLER A, DUNCAN L, STAHL E, GENOVESE G, FERNANDEZ E, COLLINS MO, KOMIYAMA NH, CHOUDHARY JS, MAGNUSSON PK, BANKS E, SHAKIR K, GARIMELLA K, FENNELL T, DEPRISTO M, GRANT SG, HAGGARTY SJ, GABRIEL S, SCOLNICK EM, LANDER ES, HULTMAN CM, SULLIVAN PF, MCCARROLL SA & SKLAR P 2014 A polygenic burden of rare disruptive mutations in schizophrenia. *Nature*, 506, 185–90. [PubMed: 24463508]

- RIDKER PM, CHASMAN DI, ZEE RY, PARKER A, ROSE L, COOK NR, BURING JE & WOMEN'S GENOME HEALTH STUDY WORKING, G. 2008 Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. *Clin Chem*, 54, 249–55. [PubMed: 18070814]
- SILVERSTEIN MD, HEIT JA, MOHR DN, PETTERSON TM, O'FALLON WM & MELTON LJ 3RD 1998 Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med*, 158, 585–93. [PubMed: 9521222]
- SOLOMON T, SMITH EN, MATSUI H, BRAEKKAN SK, CONSORTIUM I, WILSGAARD T, NJOLSTAD I, MATHIESEN EB, HANSEN JB & FRAZER KA 2016 Associations Between Common and Rare Exonic Genetic Variants and Serum Levels of 20 Cardiovascular-Related Proteins: The Tromso Study. *Circ Cardiovasc Genet*, 9, 375–83. [PubMed: 27329291]
- SUBRAMANIAN A, TAMAYO P, MOOTHA VK, MUKHERJEE S, EBERT BL, GILLETTE MA, PAULOVICH A, POMEROY SL, GOLUB TR, LANDER ES & MESIROV JP 2005 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*, 102, 15545–50. [PubMed: 16199517]
- SUCHON P, GERMAIN M, DELLUC A, SMADJA D, JOUVEN X, GYRGY B, SAUT N, IBRAHIM M, DELEUZE JF, ALESSI MC, MORANGE PE & TREGOUET DA 2017 Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk. *Sci Rep*, 7, 45507. [PubMed: 28374852]
- SURENDRAN P, DRENOS F, YOUNG R, WARREN H, COOK JP, MANNING AK, GRARUP N, SIM X, BARNES DR, WITKOWSKA K, STALEY JR, TRAGANTE V, TUKIAINEN T, YAGHOOTKAR H, MASCA N, FREITAG DF, FERREIRA T, GIANNAKOPOULOU O, TINKER A, HARAKALOVA M, MIHAILOV E, LIU C, KRAJA AT, FALLGAARD NIELSENS, RASHEED A, SAMUEL M, ZHAO W, BONNYCASTLE LL, JACKSON AU, NARISU N, SWIFT AJ, SOUTHAM L, MARTEN J, HUYGHE JR, STANCAKOVA A, FAVA C, OHLSSON T, MATCHAN A, STIRRUPS KE, BORK-JENSEN J, GJESING AP, KONTTO J, PEROLA M, SHAW-HAWKINS S, HAVULINNA AS, ZHANG H, DONNELLY LA, GROVES CJ, RAYNER NW, NEVILLE MJ, ROBERTSON NR, YIORKAS AM, HERZIG KH, KAJANTIE E, ZHANG W, WILLEMS SM, LANNFELT L, MALERBA G, SORANZO N, TRABETTI E, VERWEIJ N, EVANGELOU E, MOAYYERI A, VERGNAUD AC, NELSON CP, POVEDA A, VARGA TV, CASLAKE M, DE CRAEN AJ, TROMPET S, LUAN J, SCOTT RA, HARRIS SE, LIEWALD DC, MARIONI R, MENNI C, FARMAKI AE, HALLMANS G, RENSTROM F, HUFFMAN JE, HASSINEN M, BURGESS S, VASAN RS, FELIX JF, CONSORTIUM CH-HF, URIA-NICKELSEN M, MALARSTIG A, REILY DF, HOEK M, VOGT T, LIN H, LIEB W, ECHOGEN C, TRAYLOR M, MARKUS HF, CONSORTIUM M, HIGHLAND HM, JUSTICE AE, MAROULI E, CONSORTIUM G, et al. 2016 Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. *Nat Genet*, 48, 1151–1161. [PubMed: 27618447]
- TELL GS, FRIED LP, HERMANSON B, MANOLIO TA, NEWMAN AB & BORHANI NO 1993 Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. *Ann Epidemiol*, 3, 358–66. [PubMed: 8275211]
- TENNESSEN JA, BIGHAM AW, O'CONNOR TD, FU W, KENNY EE, GRAVEL S, MCGEE S, DO R, LIU X, JUN G, KANG HM, JORDAN D, LEAL SM, GABRIEL S, RIEDER MJ, ABECASIS G, ALTSHULER D, NICKERSON DA, BOERWINKLE E, SUNYAEV S, BUSTAMANTE CD, BAMSHAD MJ, AKEY JM, BROAD GO, SEATTLE GO & PROJECT NES 2012 Evolution and functional impact of rare coding variation from deep sequencing of human exomes. *Science*, 337, 64–9. [PubMed: 22604720]
- TWOROGGER SS, SLUSS P & HANKINSON SE 2006 Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. *Cancer Res*, 66, 2476–82. [PubMed: 16489055]
- VAN DE WATER N, TAN T, ASHTON F, O'GRADY A, DAY T, BROWETT P, OCKELFORD P & HARPER P 2004 Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. *Br J Haematol*, 127, 190–4. [PubMed: 15461625]
- VOORMAN ABJ, CHEN H, LUMLEY T, DAVID B 2017 seqMeta: An R package for meta-analyzing region-based tests of rare DNA variants. R package version 1.6.7.

- WOMEN'S HEALTH INITIATIVE STUDY GROUP 1998 Design of the Women's Health Initiative clinical trial and observational study. *Control Clin Trials*, 19, 61–109. [PubMed: 9492970]
- WU MC, LEE S, CAI T, LI Y, BOEHNKE M & LIN X 2011 Rare-variant association testing for sequencing data with the sequence kernel association test. *Am J Hum Genet*, 89, 82–93. [PubMed: 21737059]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1:

QQ plots for gene burden tests including non-synonymous variants with MAF 0.01. The WSB test using a broad definition of variant inclusion (upper left panel), the WSB test using a strict definition of variant inclusion (upper right panel), the SKAT test using a broad definition of variant inclusion (lower left panel), the SKAT test using a strict definition of variant inclusion (lower right panel).

Table 1:

Studies included in the VTE exome array analysis.

Ethnicity	Study	Country	Cases	Controls
African-American	ARIC	US	202	807
African-American	CHS	US	30	120
African-American	HVH	US	58	181
African-American	WHI	US	92	368
European	ARIC	US	433	1,734
European	CHS	US	112	448
European	FHS	US	212	848
European	HPFS/NHS/NHSII	US	2,321	2,301
European	HVH	US	841	1,788
European	MARTHA	France	2,628	3,414
European	Tromsø	Norway	528	526
European	WGHS	US	610	2,404
European	WHI	US	656	2,624
	Total		8,341	16,087

Table 2:

Association results for the three strongest associations from the rare variant WSB test.

Variant Inclusion	Gene	Beta	SE	<i>P</i>	CMAF*	# Variants [†]
Broad	<i>FAM71C</i>	3.86	0.871	9.30E-06	0.0002	2
	<i>FOXB2</i>	1.56	0.372	2.71E-05	0.0009	4
	<i>SERPINA10</i>	0.28	0.077	0.0002	0.017	8
Strict	<i>DGAT2</i>	0.64	0.179	0.0004	0.003	4
	<i>NUDT12</i>	3.11	0.877	0.0004	0.0002	2
	<i>SERPINA10</i>	0.28	0.082	0.0007	0.015	6

* CMAF = Cumulative MAF for SNPs included in the analysis

[†] Number of variants included in the analysis

Table 3:

Association results for the three strongest associations from the rare variant SKAT test.

Variant Inclusion	Gene	Qmeta [*]	P	CMAF [†]	# Variants [‡]
Broad	<i>CREB3L1</i>	596343.13	2.59E-05	0.016	7
	<i>FAM71C</i>	9844.60	3.65E-05	0.0002	2
	<i>PHC3</i>	514613.94	7.76E-05	0.017	10
Strict	<i>SRR</i>	37032.58	9.52E-05	0.0007	4
	<i>ABCF3</i>	15590.02	0.0002	0.0007	2
	<i>DSC1</i>	50186.59	0.0004	0.0014	5

^{*}The SKAT Q statistic, defined as $\sum_j w_j U_j^2$, where w_j is the weight given to SNP j , and U_j^2 is the associated score statistic

[†]CMAF = Cumulative MAF for SNPs included in the analysis

[‡]Number of Variants included in the analysis